CGEN Q2'26 Earnings: EPS estimate is (0.08) USD

Compugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.

Original reporting
Published Jul 31, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CGEN Q2'26 Earnings: EPS estimate is (0.08) USD — source image
Decision brief

The 30-second read

$CGENNeutralMed
01

Why it matters

Traders can use the stated consensus revenue ($1.28M) and EPS (-$0.08) to frame whether the upcoming print is likely to surprise and how to position into the event.

02

Market read

This is an earnings timing and consensus-expectations preview that can inform event-driven positioning and options implied-volatility expectations.

03

What to watch

The preview lacks guidance details, cash/burn commentary, and any pipeline or trial updates, which are often the real drivers of post-earnings repricing.

Relevance 6/10Novelty 5/10Timing: ahead of Aug 03 pre-market earnings release

Background

Compugen (CGEN) is set to announce Q2'26 results on Aug 03 at 7:00 AM ET (11:00 AM UTC).

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

CGEN is scheduled to report Q2'26 results Aug 03 before the open, with consensus revenue of $1.28M and EPS of -$0.08.

Expected impact

Likely elevated pre-earnings volatility around Aug 03, with direction dependent on whether reported results beat or miss the -$0.08 EPS and $1.28M revenue expectations.

Evidence & confidence

This is a forward-looking earnings preview with specific consensus numbers, which can drive positioning and implied volatility into the print, but it does not include any new post-release datapoint.

Market effects

Biotech/small-cap earnings calendar risk for oncology/biopharma names, but no sector-wide new information is disclosed.

Primarily US pre-market positioning around a single small-cap earnings event.

Limited, as the article is company-specific and does not cite global regulatory or macro catalysts.

Counterpoint

Negative consensus EPS does not guarantee downside; if expectations are already low, a modest beat could still trigger a relief rally.

Key entities

  • CGEN

    Compugen Ltd., scheduled to report Q2'26 results before market open on Aug 03.

Related articles

$CGENMed

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

$CGENMed

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.